Karyopharm Sees FY25 Xpovio Net Product Revenue at $115M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy KPTI?
Sees FY25 U.S. Xpovio net product revenue $115M. "2026 has the promise to be a transformative year for Karyopharm and the patient communities that we intend to serve, with top-line data from our Phase 3 SENTRY trial in myelofibrosis expected in March. Positive data from our SENTRY trial could unlock our opportunity to improve patient outcomes and redefine the standard-of-care in myelofibrosis. Our teams are actively preparing for regulatory filings, commercialization and the opportunity to rapidly launch with the first ever combination therapy in a multi-billion dollar market," said Richard Paulson, President and CEO of Karyopharm. "In endometrial cancer, we remain focused and on track to report top-line data from our Phase 3 XPORT-EC-042 trial in mid-2026, representing a significant opportunity to transform patient outcomes in a targeted, biomarker driven patient population. With two high-potential data readouts this year, 2026 is expected to be a catalyst-rich year that could position us for tremendous long-term value creation."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KPTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KPTI
Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is 13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.090
Low
6.00
Averages
13.83
High
21.00
Current: 6.090
Low
6.00
Averages
13.83
High
21.00
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting the latest market sentiment towards these stocks, although specific names were not disclosed, investors should pay attention to these changes for informed decision-making.
- Impact of Rating Changes: Upgrades or downgrades in ratings can directly influence the market performance of the related stocks, prompting investors to closely monitor these shifts to timely adjust their portfolios for optimized returns.
- Market Reaction Expectations: Analyst rating adjustments often trigger immediate market reactions, particularly when investors have a high level of interest in specific stocks, potentially leading to short-term price volatility.
- Information Access Channels: Investors can visit the analyst ratings page to obtain a comprehensive view of rating changes, including upgrades, downgrades, and new initiations, thereby better grasping market dynamics.
See More
Karyopharm to Report Q4 and Full Year 2025 Results on February 12, 2026
- Earnings Announcement: Karyopharm Therapeutics is set to report its fourth quarter and full year 2025 financial results on February 12, 2026, reflecting the company's ongoing advancements in cancer treatment.
- Conference Call Details: The management team will host a conference call on the same day, with investors able to dial (800) 836-8184 (local) or (646) 357-8785 (international) to join, ensuring they call at least 10 minutes prior to the start time for smooth access.
- Webcast Availability: The call will be available via live audio webcast on the company's investor website, along with accompanying slides, allowing investors to access real-time information, with an archived replay available approximately two hours after the event to enhance transparency.
- Company Background: Karyopharm is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, with its first-in-class oral XPO1 inhibitor XPOVIO® approved in the U.S. and various other countries, showcasing its leadership in the oncology sector.
See More
Karyopharm Grants Restricted Stock Units to New Employees
- Employee Incentive Program: Karyopharm Therapeutics granted a total of 1,799 restricted stock units (RSUs) to four new employees as of January 31, 2026, aimed at attracting talent and enhancing employee loyalty, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Schedule: Each RSU award will vest over three years, with 33 1/3% of the shares vesting on each of the three consecutive anniversaries of the Grant Date, ensuring continued employee contributions during their tenure with the company.
- Company Background: Karyopharm Therapeutics focuses on pioneering novel cancer therapies, with its first-in-class oral exportin 1 (XPO1) inhibitor, XPOVIO®, approved in the U.S. and regulatory approvals in over 50 territories, showcasing its leadership in cancer treatment.
- Pipeline Development: The company is developing therapies targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma, indicating its commitment to addressing significant medical needs and driving business growth.
See More
Karyopharm Projects $145 Million Total Revenue for 2025 Amid Upcoming Clinical Trials
- Clinical Trial Progress: Karyopharm anticipates releasing top-line data from the Phase 3 SENTRY trial for myelofibrosis in March 2026, which could improve patient outcomes and redefine treatment standards, opening up multi-billion dollar market opportunities for the company.
- Revenue Projections: The company expects total revenue of approximately $145 million for 2025, with net product revenue from XPOVIO (selinexor) estimated at $115 million, indicating sustained growth potential in the cancer treatment sector.
- New Drug Development: The Phase 3 XPORT-EC-042 trial for endometrial cancer is on track to report top-line data in mid-2026, and Karyopharm's collaboration with Foundation Medicine will aid in the precise recruitment of TP53 wild-type patients, enhancing treatment efficacy.
- Market Opportunities: Karyopharm's XPOVIO, as the first oral exportin inhibitor, has received approvals in multiple countries and is expected to meet the high unmet needs of cancer patients globally, driving long-term value creation.
See More
Karyopharm Grants 1,533 RSUs to New Employees as Inducement
- Employee Incentive Program: Karyopharm Therapeutics granted a total of 1,533 restricted stock units (RSUs) to two new employees, reflecting the company's commitment to attracting talent and strengthening its team.
- Grant Details: These RSU awards were granted on December 31, 2025, under the Company's 2022 Inducement Stock Incentive Plan, ensuring compliance with Nasdaq Listing Rule requirements and fostering long-term commitment from new hires.
- Vesting Arrangement: Each RSU award will vest over three years, with one-third vesting each year, which not only incentivizes employee retention but also enhances overall operational efficiency for the company.
- Strategic Implications: By implementing such incentive measures, Karyopharm not only strengthens its competitive position in cancer treatment but also lays a talent foundation for future innovation and market expansion.
See More
Karyopharm Grants 1,533 RSUs to New Employees as Inducement
- Employee Incentive Program: Karyopharm Therapeutics granted a total of 1,533 restricted stock units (RSUs) to two newly hired employees, emphasizing the company's commitment to attracting talent and strengthening its team.
- Grant Details: These RSU awards were granted on December 31, 2025, under the Company's 2022 Inducement Stock Incentive Plan, ensuring compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Arrangement: Each RSU award will vest over three years, with 33.3% vesting each year, which incentivizes employees to maintain long-term service and ensures team stability.
- Strategic Implications: By implementing such incentive measures, Karyopharm not only attracts high-quality talent but also enhances its competitive edge in cancer treatment, driving continuous innovation and growth for the company.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting the latest market sentiment towards these stocks, although specific names were not disclosed, investors should pay attention to these changes for informed decision-making.
- Impact of Rating Changes: Upgrades or downgrades in ratings can directly influence the market performance of the related stocks, prompting investors to closely monitor these shifts to timely adjust their portfolios for optimized returns.
- Market Reaction Expectations: Analyst rating adjustments often trigger immediate market reactions, particularly when investors have a high level of interest in specific stocks, potentially leading to short-term price volatility.
- Information Access Channels: Investors can visit the analyst ratings page to obtain a comprehensive view of rating changes, including upgrades, downgrades, and new initiations, thereby better grasping market dynamics.
See More
Karyopharm to Report Q4 and Full Year 2025 Results on February 12, 2026
- Earnings Announcement: Karyopharm Therapeutics is set to report its fourth quarter and full year 2025 financial results on February 12, 2026, reflecting the company's ongoing advancements in cancer treatment.
- Conference Call Details: The management team will host a conference call on the same day, with investors able to dial (800) 836-8184 (local) or (646) 357-8785 (international) to join, ensuring they call at least 10 minutes prior to the start time for smooth access.
- Webcast Availability: The call will be available via live audio webcast on the company's investor website, along with accompanying slides, allowing investors to access real-time information, with an archived replay available approximately two hours after the event to enhance transparency.
- Company Background: Karyopharm is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, with its first-in-class oral XPO1 inhibitor XPOVIO® approved in the U.S. and various other countries, showcasing its leadership in the oncology sector.
See More
Karyopharm Grants Restricted Stock Units to New Employees
- Employee Incentive Program: Karyopharm Therapeutics granted a total of 1,799 restricted stock units (RSUs) to four new employees as of January 31, 2026, aimed at attracting talent and enhancing employee loyalty, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Schedule: Each RSU award will vest over three years, with 33 1/3% of the shares vesting on each of the three consecutive anniversaries of the Grant Date, ensuring continued employee contributions during their tenure with the company.
- Company Background: Karyopharm Therapeutics focuses on pioneering novel cancer therapies, with its first-in-class oral exportin 1 (XPO1) inhibitor, XPOVIO®, approved in the U.S. and regulatory approvals in over 50 territories, showcasing its leadership in cancer treatment.
- Pipeline Development: The company is developing therapies targeting multiple high unmet need cancers, including multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma, indicating its commitment to addressing significant medical needs and driving business growth.
See More
Karyopharm Projects $145 Million Total Revenue for 2025 Amid Upcoming Clinical Trials
- Clinical Trial Progress: Karyopharm anticipates releasing top-line data from the Phase 3 SENTRY trial for myelofibrosis in March 2026, which could improve patient outcomes and redefine treatment standards, opening up multi-billion dollar market opportunities for the company.
- Revenue Projections: The company expects total revenue of approximately $145 million for 2025, with net product revenue from XPOVIO (selinexor) estimated at $115 million, indicating sustained growth potential in the cancer treatment sector.
- New Drug Development: The Phase 3 XPORT-EC-042 trial for endometrial cancer is on track to report top-line data in mid-2026, and Karyopharm's collaboration with Foundation Medicine will aid in the precise recruitment of TP53 wild-type patients, enhancing treatment efficacy.
- Market Opportunities: Karyopharm's XPOVIO, as the first oral exportin inhibitor, has received approvals in multiple countries and is expected to meet the high unmet needs of cancer patients globally, driving long-term value creation.
See More
Karyopharm Grants 1,533 RSUs to New Employees as Inducement
- Employee Incentive Program: Karyopharm Therapeutics granted a total of 1,533 restricted stock units (RSUs) to two new employees, reflecting the company's commitment to attracting talent and strengthening its team.
- Grant Details: These RSU awards were granted on December 31, 2025, under the Company's 2022 Inducement Stock Incentive Plan, ensuring compliance with Nasdaq Listing Rule requirements and fostering long-term commitment from new hires.
- Vesting Arrangement: Each RSU award will vest over three years, with one-third vesting each year, which not only incentivizes employee retention but also enhances overall operational efficiency for the company.
- Strategic Implications: By implementing such incentive measures, Karyopharm not only strengthens its competitive position in cancer treatment but also lays a talent foundation for future innovation and market expansion.
See More
Karyopharm Grants 1,533 RSUs to New Employees as Inducement
- Employee Incentive Program: Karyopharm Therapeutics granted a total of 1,533 restricted stock units (RSUs) to two newly hired employees, emphasizing the company's commitment to attracting talent and strengthening its team.
- Grant Details: These RSU awards were granted on December 31, 2025, under the Company's 2022 Inducement Stock Incentive Plan, ensuring compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Arrangement: Each RSU award will vest over three years, with 33.3% vesting each year, which incentivizes employees to maintain long-term service and ensures team stability.
- Strategic Implications: By implementing such incentive measures, Karyopharm not only attracts high-quality talent but also enhances its competitive edge in cancer treatment, driving continuous innovation and growth for the company.
See More
